HSBC cuts AstraZeneca to hold and lowers target price to £137.50 after late-stage trial failure
AI Market Summary
HSBC downgraded AstraZeneca from buy to hold and cut its price target by over 16% after a late-stage heart-disease trial failure triggered a sharp selloff. The note highlights potential erosion of investor confidence in AstraZeneca's R&D "engine", a key pillar supporting premium valuation multiples. The development raises the risk of near-term rerating pressure across European large-cap pharma, with spillover into defensives sentiment.
Impact level
● Medium
Affected assets
NCCOGOLD2USD/USDT+0.06%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
HSBC downgraded AstraZeneca (AZN.L) to hold from buy and cut its target price to £137.50 from £165, a reduction of more than 16%. The move follows the failure of a Phase III trial for a heart disease drug, which sent the shares down as much as 9% in a single session and left them down 12% for the week. Analysts said the stock’s premium valuation has long rested on confidence in its late-stage pipeline, and that consecutive R&D setbacks could trigger a reassessment.
